Clinical trial / 2019
Soy milk alongside a calorie-restricted diet reduced serum ALT and hs-CRP more than diet alone in patients with NAFLD.
A parallel randomized clinical trial evaluated the effect of consuming 240 ml of soy milk daily as part of a 500-calorie deficit diet compared to the deficit diet alone for 8 weeks in 70 patients with NAFLD. The soy milk group showed significantly greater reductions in serum alanine aminotransferase (-12.06 ± 17.61 IU/L vs. -5 ± 8.58 IU/L, p = 0.04) and hs-CRP (-1.32 ± 1.60 mg/L vs. -0.36 ± 1.54 mg/L, p = 0.01). However, changes in fatty liver grade, other liver enzymes (AST, ALP, GGT), lipid profiles, and anthropometric indices did not differ significantly between groups.
- Study type
- Parallel randomized clinical trial
- Who was studied
- 70 patients with nonalcoholic fatty liver disease (NAFLD)
- What was measured
- Grade of fatty liver, liver enzymes, lipid profile, serum hs-CRP, and anthropometric indices
THE PAPER
Effect of Soy Milk on Metabolic Status of Patients with Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial.
Eslami O, Shidfar F, Maleki Z, Jazayeri S, Hosseini AF, Agah S, Ardiyani F. J Am Coll Nutr, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.